CXCR4 and Hepatic fibrosis: Therefore, applying compound 18a in the in vivo lung and liver fibrosis models allowed us to evaluate the anti-fibrotic effect of pure ACKR3 agonism in the absence of CXCR4 antagonism, which has never been addressed before.